Q1 2025 Dr. Lal PathLabs Ltd Earnings Call Transcript
Key Points
- Achieved an 11.3% year-on-year revenue growth, reaching INR 602 crores.
- Patient volume increased by 10.4% compared to the previous quarter.
- EBITDA margin improved to 28.2%, reflecting operational efficiency.
- Strategic investments in digital infrastructure and data analytics are enhancing service outcomes.
- Integration of Suburban Diagnostics is progressing well, contributing to volume expansion.
- Suburban Diagnostics' growth was only 8%, lower than the overall company growth.
- Revenue per patient remained flat at INR 833, indicating no significant price increase.
- Margins for Suburban Diagnostics decreased to 14% from 17% in the previous quarter.
- Intense competition from hospitals and other organized players continues to be a challenge.
- Significant investments in new labs and marketing are required, which may impact short-term profitability.
Ladies and gentlemen, good day, and welcome to Dr. Lal PathLabs Q1 FY 25 earnings conference call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star, then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Siddharth Parameswaran of CDR India.
Thank you, and over to you additionally, good evening.
Everyone, and welcome to Dr. Lal PathLabs Q1 FY 25 earnings conference call. Today, we are joined by senior members of the management, including Honorary Brigadier, Dr. admin line, who is the Executive Chairman, Dr. Om Prakash Manchanda, Managing Director, Mr. Jean called Energy, Chief Executive Officer, and Mr. Prakash Goel, the Group Chief Operating Officer.
Sorry, Chief Financial Officer. My mistake, I would like to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
